Comparative Pharmacology
Head-to-head clinical analysis: FLOMAX versus MINIPRESS XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOMAX versus MINIPRESS XL.
FLOMAX vs MINIPRESS XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder base, and bladder neck, leading to relaxation of smooth muscle and improved urinary flow.
Selective alpha-1 adrenergic receptor antagonist; inhibits vasoconstriction and reduces peripheral vascular resistance via blockade of postsynaptic alpha-1 receptors on vascular smooth muscle.
0.4 mg orally once daily, approximately 30 minutes after the same meal each day. If no response after 2-4 weeks, may increase to 0.8 mg once daily.
Initial: 1 mg orally once daily at bedtime, gradually increased to 2-20 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life is approximately 14-15 hours (range 6-20 hours) in healthy adults, allowing once-daily dosing.
2–3 hours in normotensive patients; prolonged to 6–10 hours in hypertension; extended by renal impairment (up to 4–6 hours in creatinine clearance <10 mL/min)
Primarily hepatic metabolism (CYP3A4, CYP2D6) with <10% excreted unchanged in urine; fecal excretion accounts for ~76% of metabolites.
Renal (primarily as metabolites, ~90% in urine, <10% unchanged), biliary/fecal (~10%)
Category C
Category C
Alpha-1 Blocker
Alpha-1 Blocker